Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition

Cardiovascular Research

Volumn 102, Issue 1, 2014, Pages 138-147

  Bucci, Mariarosaria ^a   Vellecco, Valentina ^a   Cantalupo, Anna ^a   Brancaleone, Vincenzo ^b   Zhou, Zongmin ^c   Evangelista, Stefano ^d   Calderone, Vincenzo ^e   Papapetropoulos, Andreas ^c   Cirino, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BASILICATA   (Italy)

^c UNIVERSITY OF PATRAS   (Greece)

^d Menarini Ricerche SpA   (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

ACE inhibitors; Hydrogen sulfide; Hypertension

Indexed keywords

3 MERCAPTOSULFUR TRANSFERASE; ACETYLCHOLINE; CYSTATHIONINE BETA LYASE; CYSTATHIONINE GAMMA LYASE; CYSTEINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; HYDROGEN SULFIDE; TRANSFERASE; UNCLASSIFIED DRUG; ZOFENOPRIL; ZOFENOPRILAT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY; CELL FREE SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; EX VIVO STUDY; HEART MUSCLE RELAXATION; HYPERTENSION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASCULAR TISSUE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; CHEMISTRY; DRUG EFFECTS; MALE; METABOLISM; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; BLOOD PRESSURE; CAPTOPRIL; CYSTATHIONINE GAMMA-LYASE; HYDROGEN SULFIDE; MALE; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 84896902580     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu026     Document Type: Article

References (40)

1. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;24:983-991.
2. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002;16:149-160.
3. Hirsch AT, Talsness CE, Smith AD, Schunkert H, Ingelfinger JR, Dzau VJ. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1992;86:1566-1574.
4. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998;18:588-599.
5. Chaudhary S, Seth MK, Vats ID, Kumar K, Biswas P, Karar J et al. Sulfur-containing angiotensin-converting enzyme inhibitor 3-thienylalanine- ornithyl-proline activates endothelial function and expression of genes involved in renin-angiotensin system. J Cardiovasc Pharmacol 2013;61:311-317.
6. Julian DG. Gissi-3. Lancet 1994;344:203.
7. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999;17:115-133.
8. Ambrosioni E, Borghi C, Magnani B. The effectof the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-85.
9. Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000;130:1999-2007.
10. Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V et al. Effect of sulf-hydryl and non-sulfhydryl angiotensin-converting enzyme inhibitorson endothelialfunc-tion in essential hypertensive patients. Am J Hypertens 2007;20:443-450.
11. Mc Murray J, Chopra M. Influence of ACE inhibitors on free radicals and reperfusion injury: pharmacological curiosity or therapeutic hope? Br J Clin Pharmacol 1991;31: 373-379.
12. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005;33:42-54.
13. Unger T, Ganten D, Lang RE, Scholkens BA. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacyof converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1984;6:872-880.
14. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1982;220:63-69.
15. Wu JN, Berecek KH. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993;22:139-146.
16. Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MRet al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997;99:2375-2385.
17. Matarrese M, Salimbeni A, Turolla EA, Turozzi D, Moresco RM, Poma D et al. 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. Bioorg Med Chem 2004;12:603-611.
18. 2S is impaired in non-obese diabetic (NOD) mice. Br J Pharmacol 2008;155:673-680.
19. d'Emmanuele di Villa Bianca R, Sorrentino R, Coletta C, Mitidieri E, Rossi A, Vellecco V et al. Hydrogen sulfide-induced dual vascular effect involves arachidonic acid cascade in rat mesenteric arterial bed. J Pharmacol Exp Ther 2011; 337: 59-64.
20. Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr 2004;24:539-577.
21. Kimura H. Hydrogen sulfide as a neuromodulator. Mol Neurobiol 2002;26:13-19.
22. d'Emmanuele di Villa Bianca R, Sorrentino R, Mirone V, Cirino G. Hydrogen sulfide and erectile function: a novel therapeutic target. Nat Rev Urol 2011; 8: 286-289.
23. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C et al. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol 2010;30:1998-2004.
24. Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Modis K, Panopoulos Pet al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci USA 2012;109:9161-9166.
25. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Zaid A, Giannogonas P et al. cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasore-laxation. PLoS ONE 2012;7:e53319.
26. 2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008;322:587-590.
27. Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulph-hydration in liver and kidney of the rat. Biochem J 1982;206:267-277.
28. Bucci M, Mirone V, Di Lorenzo A, Vellecco V, Roviezzo F, Brancaleone Vet al. Hydrogen sulphide is involved in testosterone vascular effect. Eur Urol 2009;56:378-383.
29. Zhou Z, von Wantoch Rekowski M, Coletta C, Szabo C, Bucci M, Cirino G et al. Thio-glycine and L-thiovaline: biologically active H(2)S-donors. Bioorg Med Chem 2012;20: 2675-2678.
30. Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW et al. Characterizationof a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 2008;117:2351-2360.
31. Du J, Yan H, Tang C. Endogenous H2S is involved in the development of spontaneous hypertension. Beijing Da Xue Xue Bao 2003;35:102.
32. Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biophys Res Commun 2004;313:22-27.
33. Mac Mahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronaryorother occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of atherosclerosis with ramipril. J Am Coll Cardiol 2000;36:438-443.
34. Teo KK, Burton JR, Buller C, Plante S, Yokoyama S, Montague TJ. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvasratin/Enalapril Coronary Atherosclerosis Trial (SCAT). Can J Cardiol 1997;13:591-599.
35. Asselbergs FW, van der Harst P, Jessurun GAJ, Tio RA, van Gilst WH. Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vasc Pharmacol 2005;42:125-140.
36. Napoli C, Bruzzese G, Ignarro LJ, Crimi E, de Nigris F, Williams-Ignarro Set al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008;156:1154, e1151-e1158.
37. Cushman DW, Wang FL, Fung WC, Grover GJ, Harvey CM, Scalese RJ et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989;28(Suppl 2): 115S-130S; discussion 130S-131S.
38. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C et al. ACE2 deficiencymodifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008;57: 1018-1025.
39. Cushman DW, Wang FL, Fung WC, Harvey CM, De Forrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989;2:294-306.
40. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-1118.